Showing results (831-840 of 6,499) with videos related to

Sort By:
Pageof 650
Cancer Immunology, Immunotherapy : CII|July 7, 2018
Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cellsHemant K Mishra, Nabendu Pore, Emil F Michelotti, et al.
Cancer Immunology, Immunotherapy : CII|July 6, 2018
Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancerLourdes Barrera, Edgar Montes-Servín, Juan-Manuel Hernandez-Martinez, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1991
Retrovirus-mediated gene transfer into CD4+ and CD8+ human T cell subsets derived from tumor-infiltrating lymphocytes and peripheral blood mononuclear cellsS Morecki, E Karson, K Cornetta, et al.
Cancer Immunology, Immunotherapy : CII|May 11, 2017
IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironmentDavid H Munn, Madhav D Sharma, Theodore S Johnson, et al.
Cancer Immunology, Immunotherapy : CII|May 13, 2017
Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapiesUpendra P Hegde, Bijay Mukherji
Cancer Immunology, Immunotherapy : CII|June 15, 2017
A phase II study of ipilimumab plus temozolomide in patients with metastatic melanomaSapna P Patel, Dae Won Kim, Roland L Bassett, et al.
Cancer Immunology, Immunotherapy : CII|July 9, 2017
Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancerRobert Wesolowski, Megan C Duggan, Andrew Stiff, et al.
Cancer Immunology, Immunotherapy : CII|July 5, 2017
Immune biomarkers for chronic inflammation related complications in non-cancerous and cancerous diseasesYaron Meirow, Michal Baniyash
Cancer Immunology, Immunotherapy : CII|August 31, 2016
NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cellsJohn O Richards, Alex J Albers, Thomas S Smith, et al.
Cancer Immunology, Immunotherapy : CII|September 2, 2016
A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomasMegan C Duggan, Caroline Jochems, Renee N Donahue, et al.
Pageof 650